Loading data for CHRS — first visit, this takes a few seconds.
Coherus Oncology, Inc. (CHRS)
NasdaqGM: CHRS
· Real-Time Price · USD
1.42
+0.05 (3.65%)
At close: Sep 04, 2026, 8:00 PM
1.42
+0.00%
Pre-market: 4:00 AM
The price, the headline numbers and the latest news, in one place.
Coherus Oncology, Inc. (CHRS) Stock Price, Analysis & Data
No data available
| Bid | 1.51 |
| Market Cap | 219M |
| Revenue (ttm) | 50.9M |
| Net Income (ttm) | -161M |
| 0.94 | |
| -1.24 | |
| n/a | |
| -2.25 | |
| P/B (ttm) | 3.60 |
| P/S (ttm) | 4.31 |
| Earnings Date | Nov 5, 2026 |
| Ask | 1.9 |
| Volume | 304,113 |
| Avg. Volume (20D) | 985,763 |
| Open | 1.38 |
| Previous Close | 1.37 |
| Day's Range | 1.38 - 1.44 |
| 52-Week Range | 1.09 - 2.62 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting inter...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2014
Employees 144
Stock Exchange NasdaqGM
Ticker Symbol CHRS
Website https://www.coherus.com
Financial Performance
In 2025, Coherus Oncology's revenue was 42.17M, an increase of 59.81% compared to the previous year's 26.39M. Earnings were 168.02M, an increase of 489.41%.
Financial StatementsEarnings Surprise
Coherus Oncology has released their quarterly earnings on Aug 5, 2026:
- Revenue of $14.31M misses estimates by $0, with 39.53% YoY growth.
- EPS of -0.19 misses estimates by -0.08, with 44.12% YoY growth.
Coherus Oncology, Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2